In addition, analysis of Gene Expression Omnibus (GEO) database and immunohistochemical staining confirmed the increased expression of FSTL3 in the liver of NAFLD patients with fibrosis. This evidence concerns the gene FSTL3 and metabolic dysfunction-associated steatotic liver disease.